ArticleFrontiers in immunology2025
Residual pattern of primary tumor and lymph node in ESCC treated with nCRT with or without pembrolizumab: an analysis from a prospective cohort.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A bibliometric analysis of minimally invasive esophagectomy for esophageal cancer (2005-2024): mapping the knowledge landscape and future trends.Surgical endoscopy · 2026Article
- Editorial: Checkpoint immunotherapy: reshaping the landscape of gastrointestinal cancer treatment, volume II.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemoradiotherapy (nCRT) is recommended as the standard of care for locally advanced esophageal squamous cell carcinoma (ESCC). Adding immunotherapy to nCRT (nICRT) has gained attention in clinical practice. We evaluated the differences in clinicopathologic outcomes and the patterns of lymph node metastasis in patients receiving nCRT and nICRT for locally advanced ESCC. Methods: A total of 208 ESCC patients who completed transthoracic esophagectomy after neoadjuvant treatment were enrolled. Clinicopathologic parameters and the rates of lymph node metastasis in each station classified using both the eighth edition of the American Joint Committee on Cancer (AJCC) esophageal cancer staging system and the 11th edition of the Japanese Classification of Esophageal Cancer (JCEC) standard were recorded and evaluated. Results: The rates of pathological complete response (pCR) and major pathological response (MPR) were 44.9% in nICRT vs. 37.0% in nCRT ( Conclusion: nICRT followed by surgery may lead to a promising pathological response. For patients with lymph node metastasis in certain regions, nICRT should be considered as a better preoperative treatment option.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.